Bartberger, Michael D.

Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors

Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry

Protein Kinase Regulation and GTPase SignalingHeterocyclic Compound Synthesis and Bioactivity

Cited by 765

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 290

A biochemical rationale for the discrete behavior of nitroxyl and nitric oxide in the cardiovascular system

Miranda, K. M., Paolocci, N., Katori, T., Thomas, D. D., Ford, E., Bartberger, M. D., Espey, M. G., Kass, D. A., Feelisch, M., Fukuto, J. M., et al. (2003) · Proceedings of the National Academy of Sciences

Nitric Oxide and Endothelin EffectsRedox biology and oxidative stress

Cited by 283

Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1 H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C

Shin, Y., Jeong, J. W., Wurz, R. P., Achanta, P., Arvedson, T., Bartberger, M. D., Campuzano, I. D. G., Fucini, R., Hansen, S. K., Ingersoll, J., et al. (2019) · ACS Medicinal Chemistry Letters

Protein Kinase Regulation and GTPase SignalingHeterocyclic Compound Synthesis and Bioactivity

Cited by 113

Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors

Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity

Cited by 82